Advanced in Relapsing Polychondritis

Shengyun Y. Liu

NO. 1, Jianshe East Road, 
Zhengzhou, CN 
Advanced in Relapsing Polychondritis
NO. 1, Jianshe East Road, 
Zhengzhou, CN 
OverviewLocationsClinical Research

Overview

Shengyun Liu practices in Zhengzhou, China. Liu is rated as an Advanced expert by MediFind in the treatment of Relapsing Polychondritis. Their top areas of expertise are Relapsing Polychondritis, Dermatomyositis, Polymyositis, and Myositis.

Their clinical research consists of co-authoring 107 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Relapsing Polychondritis.

Locations

NO. 1, Jianshe East Road, Zhengzhou, 450052, China
Other Locations
1 Eastern Jianshe Road, Zhengzhou, 450052, China
No. 1 Jianshe Road, Zhengzhou, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
Enrollment Status: Terminated
Publish Date: June 21, 2022
Intervention Type: Drug, Other
Study Drug: Hemay005
Study Phase: Phase 2
View 2 Less Clinical Trials

107 Total Publications

Molecular epidemiological characteristics and risk factors analysis of Carbapenem-resistant Enterobacterales intestines colonization of neonates in Shenzhen region
Molecular epidemiological characteristics and risk factors analysis of Carbapenem-resistant Enterobacterales intestines colonization of neonates in Shenzhen region
Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Published: July 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 36 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile